Degrasyn-like symmetrical compounds: possible therapeutic agents for multiple myeloma (MM-I)

A new class of degrasyn-like symmetrical compounds was designed, synthesized, and tested against B cell malignancy cell lines, including multiple myeloma and mantle cell lymphoma. The lead compounds, T5165804 and CP2005, demonstrated superior nanomolar potency compared to degrasyn and effectively inhibited Usp9x activity both in vitro and in cells. These findings highlight their potential as promising cancer therapeutics.